Skip to main content

Table 2 Primary efficacy and safety outcomes

From: Efficacy and safety of long-term use of a positive expiratory pressure device in chronic obstructive pulmonary disease patients, a randomized controlled trial

 

Intervention group

P

Control group

P

Intervention group

D (T0 minus T1)

Control group

D (T0 minus T1)

P

T0

T1

T0

T1

6MWD, m

545 ± 79

618 ± 69

 < 0.001

525 ± 106

526 ± 109

0.875

− 73 ± 24

− 1 ± 19

 < 0.001

Initial Borg-Dyspnea

0 (0–0.25)

0 (0–0)

0.102

0 (0–0)

0 (0–0)

1

0 (0–0.25)

0 (0–0)

0.083

End Borg-Dyspnea

2 (0.75–3)

1 (0.5–1.5)

0.003

1 (0.5–2)

0.75 (0.5–2)

0.257

1 (0.5–1.75)

0 (0–0.38)

0.002

Initial Borg-Fatigue

0 (0–0)

0 (0–0)

1

0 (0–0)

0 (0–0)

1

0 (0–0)

0 (0–0)

1.0

End Borg-Fatigue

0.5 (0.5–2)

0.5 (0–1)

0.016

0.75 (0.5–1)

0.75 (0.5–1)

1

0.5 (0–0.75)

0 (0–0)

0.022

PETCO2, mmHg

36 ± 3

34 ± 3

 < 0.001

36 ± 3

36 ± 3

0.082

2 ± 1

− 0.25 ± 0.45

 < 0.001

  1. Definition of abbreviations: 6MWD = 6-min walking distance; Initial Borg-Dyspnea = Modified Borg scale for dyspnea at the beginning of the 6-min walk test; End Borg-Dyspnea = Modified Borg scale for dyspnea at the end of the 6-min walk test; Initial Borg-Fatigue = Modified Borg scale for fatigue at the beginning of the 6-min walk test; End Borg-Fatigue = Modified Borg scale for fatigue at the end of the 6-min walk test; PETCO2 = partial pressure of end-tidal carbon dioxide. Data are shown as mean ± SD or median ([Q1, Q3]). T0 refers to the time when subjects were enrolled. T1 refers to the time when subjects were followed up at 2 months after enrollment. D (Difference) refers to the value at T0 minus the value at T1 (D = T0 minus T1). In order to determine the statistical significance, we used independent sample t test, Mann–Whitney U test, paired t-test or Wilcoxon test